Lenacapavir

Common card · No. 222614

Lenacapavir, sold under the brand names Sunlenca among others, is an antiretroviral medication used to treat and prevent HIV/AIDS. It is taken by mouth or by subcutaneous injection. Lenacapavir is a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor. It is given by mouth and as a subcutaneous injection. The most common side effects include reactions at the injection site and nausea. Lenacapavir was first authorized for medical use in the European Union in August 2022, in Canada in November 2022, and in the United States in December 2022. It is the first of a class of drugs called capsid inhibitors to be approved by the US Food and Drug Administration (FDA) for treating HIV/AIDS. The FDA considers it to be a first-in-class medication. In 2025, lenacapavir was approved for HIV prevention (PrEP) in the United States, the European Union, and Canada and introduced in China. In 2026, it became available for PrEP as Yeytuo in Australia. India has sought a waiver to bring faster approval...

Read on Wikipedia · Image Reba16 (talk), Public domain